EMA Authorised: Iqirvo (Elafibranor) — Ipsen Pharma

View source ↗

Summary

The EMA authorised Iqirvo (elafibranor) for liver cirrhosis and biliary diseases with conditional approval, and it has orphan medicine designation.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Biliary Diseases
• Liver Cirrhosis

Drugs mentioned

• IQIRVO (ELAFIBRANOR)

Snippet

Status: Authorised. Therapeutic area: Liver Cirrhosis, Biliary. MAH: Ipsen Pharma. Decision date: 28/07/2025. Conditional approval. Orphan medicine